The potentially $1.4 billion alliance will see the two companies collaborate on “macrocycles” that could yield oral ...

Nearly a dozen biotechnology firms have matched or raised more than $300 million in their initial public offerings in 2026, a figure not seen since new stock sales peaked in 2021, according to ...

Armed with $180 million and a dual-acting antibody for eczema, the startup is capitalizing on a change in sentiment that’s led to a sudden spike in reverse merger deals.

Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course ...

Once disparaged, reverse mergers have become so popular that some deal experts question whether there are enough quality ...

The Danish drugmaker will use Claude Science as part of a goal to become "the world’s most AI-driven healthcare company." ...

Proceeds from the deal, which hands Novartis global rights to a technology developed by Sironax, will help advance three ...

First teased in June and formally announced Tuesday as part of “Operation Trialblazer,” the program will partner drugmakers ...

Skyhawk Therapeutics, a Boston-based biotechnology company, has unveiled final results from a small study testing a once-daily, “RNA splicing” pill as a treatment for Huntington’s disease.

AI is evolving from interactive chats to automated workloads driven by agentic tools, compressing timelines and enabling faster outcomes. A new reference architecture running on the Dell Pro Max with ...

As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings ...

A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk ...